| Patent application number | Description | Published |
|---|
| 20080269067 | Companion diagnostic assays for cancer therapy - A method for classifying cancer patients as eligible to receive cancer therapy comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy, such as therapy with a Bcl-2 family inhibitor, and for monitoring patient response to therapy. | 10-30-2008 |
| 20100144554 | METHODS FOR ASSEMBLING PANELS OF CANCER CELL LINES FOR USE IN TESTING THE EFFICACY OF ONE OR MORE PHARMACEUTICAL COMPOSITIONS - The present invention relates to algorithms for use in defining genomic subgroups of tumors and cancer cell lines. The present invention also relates to methods for assembling panels of tumors and cancer cell lines according to genomic subgroups for use in testing the efficacy of one or more pharmaceutical compounds in the treatment of subjects suffering from at least one cancer. | 06-10-2010 |
| 20100145893 | GENOMIC CLASSIFICATION OF NON-SMALL CELL LUNG CARCINOMA BASED ON PATTERNS OF GENE COPY NUMBER ALTERATIONS - The invention is directed to methods and kits that allow for classification of non-small cell lung carcinoma tumors and cell lines according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same. | 06-10-2010 |
| 20100145894 | GENOMIC CLASSIFICATION OF COLORECTAL CANCER BASED ON PATTERNS OF GENE COPY NUMBER ALTERATIONS - The invention is directed to methods and kits that allow for classification of colorectal cancer cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same. | 06-10-2010 |
| 20100145897 | GENOMIC CLASSIFICATION OF MALIGNANT MELANOMA BASED ON PATTERNS OF GENE COPY NUMBER ALTERATIONS - The invention is directed to methods and kits that allow for classification of malignant melanoma cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same. | 06-10-2010 |
| 20100184026 | Companion Diagnostic Assays For Endothelin Receptor Antagonists - Methods for identifying cancer patients eligible to receive endothelin receptor antagonist therapy and for monitoring patient response to endothelin receptor antagonist therapy comprise assessment of the expression levels of at least one of PAI-1, uPA, TGFbeta2, IL-6, IL-8 and OPG in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive endothelin receptor antagonist therapy and of determination of patient response to the therapy. | 07-22-2010 |
| 20100196907 | MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY - The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients' response to such therapy. | 08-05-2010 |
| 20100234239 | METHODS AND COMPOSITIONS FOR IDENTIFYING, CLASSIFYING AND MONITORING SUBJECT HAVING BCL-2 FAMILY INHIBITOR-RESISTANT TUMORS AND CANCERS - The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-x | 09-16-2010 |
| 20110105341 | Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer - The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci. | 05-05-2011 |
| 20110130295 | Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer - Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus. | 06-02-2011 |
